The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa by Jacobson, Daniel R et al.
ORIGINAL ARTICLE
The prevalence and distribution of the amyloidogenic
transthyretin (TTR) V122I allele in Africa
Daniel R. Jacobson1, Alice A. Alexander2, Clement Tagoe3, W. T. Garvey4, Scott M. Williams5,
Sara Tishkoff6, David Modiano7, Sodiomon B. Sirima8, Issa Kalidi9, Amadou Toure10 & Joel N. Buxbaum11
1Veterans Administration Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
2Research Service, Veterans Administration Boston Healthcare System, Boston, Massachusetts
3Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
4Department of Nutrition Sciences, University of Alabama School of Medicine, Birmingham, Alabama
5Department of Genetics, Geisel School of Medicine, Dartmouth University, Hanover, New Hampshire
6Departments of Genetics and Biology, University of Pennsylvania, Philadelphia, Pennsylvania
7Dipartimento di Sanita Pubblica e Malattie Infettive, Sapienza Universita di Roma, Rome, Italy
8Centre National de Recherche et Formation sur le Paludisme, Ministere de la Sante, Ouagadougou, Burkina Faso
9Hematology Laboratory, Ho^pital Saint-Louis, Paris, France
10Institut National de Recherche en Sante Publique, Bamako, Mali
11Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California
Keywords
Africa, amyloidosis, slave trade, transthyretin
Correspondence
Joel N. Buxbaum, Department of Molecular
and Experimental Medicine, The Scripps
Research Institute, 10550 N. Torrey Pines
Road, La Jolla, CA 93037.
Tel: 858 784 8885;
Fax: 858 784 8891;
E-mail: jbux@scripps.edu
Funding Information
The study was supported by the National
Institutes of Health (NIH) grant R01AG19259
(J. N. B.).
Received: 1 March 2016; Revised: 25 May
2016; Accepted: 30 May 2016
Molecular Genetics & Genomic Medicine
2016; 4(5): 548–556
doi: 10.1002/mgg3.231
Abstract
Background
Transthyretin (TTR) pV142I (rs76992529-A) is one of the 113 variants in the
human TTR gene associated with systemic amyloidosis. It results from a G to A
transition at a CG dinucleotide in the codon for amino acid 122 of the mature
protein (TTR V122I). The allele frequency is 0.0173 in African Americans.
Methods
PCR-based assays to genotype 2767 DNA samples obtained from participants in
genetic studies from various African populations supplemented with sequencing
data from 529 samples within the 1000 Genomes Project.
Results
The rs76992529-A variant allele was most prevalent (allele frequency 0.0253) in
the contiguous West African countries of Sierra Leone, Guinea, Ivory Coast,
Burkina Faso, Ghana, and Nigeria. In other African countries, the mean allele
frequency was 0.011.
Conclusions
Our data are consistent with a small number of founder carriers of the amy-
loidogenic TTR V122I (p.Val142Ile) allele in southern West Africa, with no
apparent advantage or disadvantage of an allele carrying newborn reaching
adulthood. In U.S. African Americans, the allele represents a significant risk for
congestive heart failure late in life. If clinical penetrance is similar in African
countries with high allele frequencies, then cardiac amyloidosis could also rep-
resent a significant cause of heart disease in the elderly in those populations.
Introduction
Despite the predominant role of genomics, genome-wide
association studies, and deep sequencing technology in
modern genetics, the study of well-defined single base
changes causing clinical disease in large populations
remains important, particularly as therapies become avail-
able for such diseases. Furthermore, the disease-associated
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variants can sometimes provide useful information regard-
ing their evolutionary effect and the history of the carrier
populations.
Transthyretin (TTR) is a homotetrameric, nonglycosy-
lated serum and cerebrospinal fluid protein carrier of thy-
roxine and retinol-binding protein charged with retinol
(Buxbaum 2007). Each TTR monomer contains 127
amino acids. It is synthesized in the liver, choroid plexus,
retinal epithelium, pancreas, and neurons (Buxbaum
2007; Li et al. 2011). It is a systemic carrier for thyroxine
(T4) and retinol-binding protein charged with retinol and
has a critical function in transporting T4 into the central
nervous system during a relatively narrow developmental
window. Studies of homozygous Ttr knockout mice show
significant structural disruption in the hippocampus with
a quantitative deficit in neuroblast number in the
supraventricular zone and neuronal loss in the CA3
region (Buxbaum et al. 2014). These are accompanied by
deficits in spatial learning in adult mice (Sousa et al.
2004). It has been hypothesized that the phenotype is
developmental. Neuronally synthesized TTR has been
shown to behave as a stress protein, protective in trans-
genic murine models of human Ab deposition with
increased synthesis in human Alzheimer’s disease (Wang
et al. 2014).
The protein is encoded by a single-copy gene (TTR)
(NCBI reference sequence: NC_000018.10) on human
chromosome 18 (Wallace et al. 1985). The gene is well
conserved in humans with few variants relative to genes
encoding other serum proteins and genes of the same size
(Abecasis et al. 2010). A single protein polymorphism, a
substitution of a serine for glycine at position 6 in the
mature protein, occurs in approximately 12% of subjects
of European descent (allele frequency 0.06) and to date
seems unassociated with disease (Jacobson et al. 1995). Of
70 Africans screened, none were shown to carry this
mutation, but it occurs in 2.5% of African Americans
(Jacobson et al. 1995). The African American/White
American allele frequency ratio of 0.0125/0.06 (0.21) is
consistent with the mean estimate of admixture
(0.17  0.063) of European and African genes found in
several studies across the U.S. population (Mersha and
Abebe 2015). There is an additional rare coding sequence
variant TTR Thr119Met (p.Thr139Met), which is kineti-
cally very stable and has been reported to be associated
with increased longevity in a large Danish population
study (Hornstrup et al. 2013). The explanation for the
longevity effect is unclear. Despite a significant number of
large scale population surveys searching for variants, there
has been no reported instance of a human completely
lacking TTR.
To date there have been 123 amino acid substitutions,
one deletion and one synonymous base substitution
reported for the transthyretin protein and its encoding
gene. Twelve have not been associated with tissue-com-
promising TTR deposits, while in one instance the clinical
amyloidogenicity has not been established. The amino
acid variants have been shown to result in decreases in
either the thermodynamic or kinetic stability of the tetra-
mer and cause human disease (OMIM 176300.0009)
(http://www.amyloidosismutations.com/mut-attr.php).
The variants produce autosomal dominant diseases in
which the tetramer dissociates into its constituent mono-
mers that subsequently misfold and aggregate forming tis-
sue oligomers and fibrils (Johnson et al. 2012). The
aggregates are cytotoxic and may also compromise func-
tion on a displacement basis, depending on the target
organ (Reixach et al. 2004). Most TTR variants have been
described in only one or a few kindreds (Rowczenio et al.
2014). The most common variants associated with disease
are pV50M (TTR V30M) and pV142I (TTRV122I). Both
arose from transitions at CpG dinucleotides, a mutational
“hot spot” (Cooper and Youssoufian 1988), as did the
normal population variants TTR pG26S (TTR G6S) and
pT139M (TTR T119M). Among the amyloidogenic TTR
mutations, TTR V122I is unusual for its overwhelmingly
predominant occurrence in individuals of documented
African descent.
The heart is the major organ showing amyloid deposi-
tion in the pV142I (TTR V122I) carriers. It was first
described in 1988 in an African American man with car-
diac amyloidosis who was homozygous for the G?A
transition at rs76992529 (Gorevic et al. 1989; Jacobson
et al. 1990). Many other reports have confirmed the asso-
ciation of the variant with cardiac amyloidosis in elderly
African Americans and it is now recognized as a cause of
heart failure when the allele is present in either the
heterozygous or homozygous state (Jacobson et al. 1990;
Nichols et al. 1991). Population studies have determined
that the prevalence of the TTR rs76992529-A allele in
African Americans is 0.0173 (Jacobson et al. 2015). A
small number of kindreds carrying the allele without
identifiable African ancestry have been reported (Gillmore
et al. 1999; Asl et al. 2001; Ammirati et al. 2012) (Cap-
pelli et al. 2015; Damy et al. 2015). The amyloidogenic
allele is an infrequent but valid ancestry informative mar-
ker. It appears that in the heterozygous state the allele is
clinically silent until the seventh decade of life or later.
Homozygous individuals develop disease about 10 years
earlier (Reddi et al. 2014). Given the late age of clinical
impact, the allele is likely to be evolutionarily neutral.
One previous study reported the allele frequency in
small selected African populations: it was found in 1/55
South African Zulus, 0/34 South African Xhosas, and 0/9
Nigerians (Afolabi et al. 2000). Since the African Ameri-
can population is largely descended from African slaves
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brought to the western hemisphere from West Africa in
the 16th to 19th centuries (Curtin 1969), we elected to
investigate its origin(s) by determining the frequency of
the TTR V122I allele in various modern African cohorts.
Methods
Ethical compliance
De-identified DNA samples from 14 modern African
countries were obtained with informed consent by inves-
tigators studying the genetics of a variety of diseases not
known to be related to TTR and laboratories interested in
the nature of genetic differences among African popula-
tions (Table 1). The samples from the Gambia obtained
specifically for this study were approved by the Gambia
ethics committee of the Medical Research Council
(MRC). The samples were provided to us with informa-
tion about the country and, in some cases, the village
and/or tribe of origin. We have also included data from
529 African DNA samples analyzed and reported in the
“1000 Genomes Project” (Abecasis et al. 2010).
The TTR rs76992529-A allele was identified using PCR-
based assays developed in our laboratory (Jacobson 1992)
(Alexander et al. 2004) except in the data available from
the 1000 Genomes Project in which complete DNA
sequencing was performed (Abecasis et al. 2010).
Results
Of the roughly 2900 samples tested in our laboratories,
successful results were obtained in 2767. The prevalence
of the TTR allele encoding pV142I was highest in six con-
tiguous countries of West Africa, ranging from Nigeria in
the east to Guinea in the west (Table 1 and Fig. 1). The
overall allele frequency in this area was 0.0253, with each
of the individual countries having an allele frequency of
at least 0.021. In contrast, the allele frequencies in the
other 10 African countries studied ranged from 0 to
0.013, with an overall frequency in those countries of
0.011. The 0.0253 frequency in the high-prevalence area
was statistically different from the frequency in samples
studied from outside this area (Table 1, Fig. 1)
(P = 0.0001) (two-tailed Z test).
Discussion
It is striking that within the African countries examined
in this study, the frequency of the TTR pV142I (TTR
V122I)-encoding allele was significantly higher in one
contiguous geographic area of West Africa (overall allele
prevalence 0.0253, ranging from 0.021 to 0.037 in the
individual countries studied) than elsewhere in Africa
(allele prevalence 0.010–0.011). The overall allele preva-
lence of 0.0253 in the high-prevalence area indicates that
about 5.1% of the population is expected to be heterozy-
gous for the variant allele. While the allele prevalence is
significantly lower in other African regions, it was present
wherever we were able to sample throughout sub-Saharan
and western Africa (Fig. 1, Table 1).
Since the Ghanaian samples were obtained from 948
newborns and 264 adults, we could compare the allele
frequencies in two different age groups from the same
population (as determined in a single geographic area).
The allele frequency was nearly identical in the newborns
(49/1896; 0.026) and the adults (13/528; 0.025) from
Accra. These data, coupled with the late age of onset of
the allele-associated disease, support the conclusion that
the allele does not influence survival to adulthood and is
unlikely to be under positive or negative selective evolu-
tionary pressure. The allele prevalence in African Ameri-
cans is close to that in the modern West African
countries that were the geographic center of the slave
trade suggesting that the gene was present in similar pro-
portions in the population ancestral to modern African
Americans and had little effect on survival in North
America (Curtin 1969).
A recent analysis of the African samples from the
“1000 Genomes Project” showed that the G to A transi-
tion responsible for the variant amino acid occurred on
five different haplotypes (Polimanti et al. 2014). Four of
these differed from the haplotype containing the ancestral
allele at 12 different positions within the confines of the
TTR gene and were identical at all but one base, indicat-
ing a single founder haplotype that acquired noncoding
mutations after the appearance of the amyloidogenic TTR
V122I allele. The second potential founder haplotype dif-
fered from the ancestral haplotype at 13 positions and
from the other possible founder haplotype at 12 positions,
five of which it shared with the ancestral allele suggesting
a second founding event or a more complex set of alter-
ations in the gene after the initial appearance of
rs76992529. In any case, despite the origin of the allele at
a CpG dinucleotide, a so-called genetic “hot spot,” the
number of founder haplotypes is small. Previous haplo-
type analyses in African American carriers of the allele
also suggested a small number of founders in the descen-
dants of the original slave population (Jacobson et al.
1998).
Genetic, epigenetic, and environmental factors have
been proposed as being responsible for variation in the
clinical penetrance, that is, clinically important TTR amy-
loid deposition, of any TTR mutation. The first-described
and most extensively studied disease-associated TTR vari-
ant, TTR pV50M (TTR V30M) was identified in Portugal,
then Sweden, and subsequently Japan, and has since been
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found globally (Andrade 1952; Araki et al. 1968; Ander-
sson 1976). The age of the allele has been estimated to be
26 generations (750 years) in Portugal, 15 generations
(375 years) in Sweden (Zaros et al. 2008), and perhaps
older in Italy (Iorio et al. 2014). Analysis of intronic hap-
lotypes revealed multiple founders in Japan, but single
founders in Portugal and Sweden (Yoshioka et al. 1989;
Zaros et al. 2008). More recent studies have identified
multiple haplotypes across Europe as well (Reilly et al.
1995; Soares et al. 2004). There are significant differences
in clinical penetrance of TTRV30M among the carriers in
different populations, particularly with respect to age of
onset (Koike et al. 2002) (Hellman et al. 2008). We have
suggested that disease penetrance is conditioned by epi-
static interactions with other genes, the products of which
can influence the stability of the tetramer (Soares et al.
2005). Support for that idea has recently been reported
independently (Santos et al. 2015). Others have hypothe-
sized that variation at transcription factor binding sites
within populations resulting in different transcription
levels presumably increased, resulting in increased serum
TTR concentrations, could also be responsible for differ-
ent degrees of clinical penetrance (Polimanti et al. 2014).
While there are no available data regarding hepatic TTR
transcription in different carriers of the same amyloido-
genic allele, we think this unlikely since serum TTR con-
centrations tend to be lower rather than higher in carrier
subjects even before there is detectable tissue deposition.
Studies of polymorphisms in a microRNA binding site
in the promoter region of TTR V30M (pV50M) carriers
in Sweden, while initially suggesting an explanation for
the apparent late onset in Swedish carriers, could not be
confirmed (Olsson et al. 2010; Norgren et al. 2012). In
individuals carrying TTR V30M, it appears that the
Table 1. Frequency of TTR V122I in African populations.
Country/Region Population source V122I/Total alleles
Allele
prevalence
(sample) V122I alleles Total alleles
Allele prevalence
(country)
Burkina Faso Modiano et al. (1999) 3 120 0.025
Ghana Total 61 2424 0.025
Williams et al. (2000) 13/528 0.025
Present study 48/1896 0.026
Guinea Zimmerman et al. (1995) 2 56 0.036
Ivory Coast Zimmerman et al. (1995) 3 82 0.037
Sierra Leone Total 31 1174 0.026
Zimmerman et al. (1995) 6/100 0.060
Jackson et al. (2005) 22/904 0.024
Mende Abecasis et al. (2010) 3/170 0.018
Nigeria Total 12 570 0.021
Vulliamy et al. (1991) 0/122 <0.008
Afolabi et al. (2000) 0/18 <0.055
Esan Abecasis et al. (2010) 6/198 0.030
Yoruba Abecasis et al. (2010) 6/232 0.026
Total, high-prevalence area 112 4426 0.0253
Gambia Total 8 636 0.013
Cooke et al. (2004);
Sirugo et al. (2004)
5/410 0.012
Abecasis et al. (2010) 3/226 0.013
Guinea-Bissau Zimmerman et al. (1995) 1 78 0.013
Mali Kalidi et al. (1988) 1 130 0.008
Senegal Zimmerman et al. (1995) 1 132 0.008
Tanzania Henn et al. (2008) 3 254 0.012
Cameroon Henn et al. (2008) 3 230 0.013
Kenya 1 264 0.004
Luhya (Kenya) Abecasis et al. (2010) 1/232 0.009
Other Kenya 0/32 <0.030
South Africa 3 360 0.008
Xhosa Afolabi et al. (2000) 0/68 <0.015
Zulu Afolabi et al. (2000) 1/110 0.009
Xhosa Rousseau et al. (1985) 2/182 0.011
Total, outside high-prevalence area 21 2084 0.010
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parent of inheritance (POI) has a significant effect on dis-
ease penetrance, carrier sons of carrier mothers having
earlier onset, and more severe disease (Sousa et al. 1991).
Some studies have suggested that the POI is related to
mitochondrial genotype; however, it does not appear that
the entire effect can be attributed to mitochondrial inher-
itance (Olsson et al. 2008; Bonaiti et al. 2010). One can
assume that the same phenomena will prevail for disease
related to all the amyloidogenic TTR mutations including
pV142I (TTRV122I).
The mechanism of TTR amyloid formation is similar
regardless of the nature of the specific mutation, that is,
dissociation of the TTR tetramer due to reduced thermo-
dynamic or kinetic stability, which allows the released
monomers to misfold and aggregate (Johnson et al.
2012). It is likely that genetic or epigenetic factors that
influence the development of disease operate in a similar
manner regardless of the specific mutation, having a
greater or lesser effect depending on the stability of the
variant.
Among the samples from Sierra Leone, Cameroon,
Tanzania, Burkina Faso, Nigeria, and South Africa, the
variant allele was found in samples from multiple tribal
origins and language groups (Tables 1 and 2). Our sam-
ple sizes were not large enough to determine whether the
differences in allele frequencies among tribes were statisti-
cally significant. In the absence of larger sample sizes and
haplotype analysis in those individuals we cannot deter-
mine whether these represented rare individual founders
or migrants into the groups from areas in which the allele
was present at higher frequencies.
The similar allele frequencies in newborn and adult
Ghanaians suggest that the TTR V122I (pV142I) allele
does not confer an advantage or disadvantage in reaching
adulthood in the Ghanaian environment. Similarly, the
0.0173 allele frequency in U.S. African Americans, allow-
ing for an average admixture of 17% with European
genes, is consistent with the 0.0253 frequency in Africans
in the high-prevalence area, and suggests that there is lit-
tle selection against allele carriers in the United States
environment. Hence, current allele frequencies across
Africa may reflect its distribution at the time of the
Atlantic slave trade from the 15th to 19th centuries A.D.
The TTR V122I (pV142I) allele frequencies are highest
in the non-Bantu-speaking Niger-Kordofanian-derived
Figure 1. Distribution of the TTR V122I allele
in Africa (see Table 1). The allele frequencies
are indicated by color. Populations from the
countries colored light gray were not analyzed.
Table 2. TTR V122I allele prevalence in specific tribes in Tanzania,
Cameroon, and Sierra Leone.
Tribe TTR V122I TTR V122V Allele frequency
Tanzania and Cameroon
Turu 0 56 <0.018
Sandawe 1 61 0.016
Burunge 2 50 0.038
Maasai 0 58 <0.017
Bakola 0 56 <0.018
Bamoun 1 55 0.018
Zime 2 46 0.042
Sierra Leone
Creole 4 70 0.054
Shabro 1 1 1
Mende 9 236 0.038
Temne 3 195 0.015
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populations from Sierra Leone, Ghana, Cote d’Ivoire, etc.
Broad genetic studies have indicated that this is the ances-
try that is mostly highly represented in African Americans
(Tishkoff et al. 2009; Bryc et al. 2010). Interestingly, the
frequencies of the TTR V122I (pV142I) allele are low in
the countries immediately adjacent to the north and west
(Gambia, Guinea-Bissau, Mali, and Senegal) as well as
those to the south and east.
The major population movement as judged initially by
language patterns across Africa was the so-called Bantu
expansion from 1000 B.C. to 500 A.D. During that period
Bantu language-speaking people spread, apparently in sev-
eral stages, from a relatively small area in what is now the
southeastern border of Nigeria and Cameroon, south and
eastward, dispersing throughout the southern half of the
continent. In our study, the lower allele frequency in the
Cameroonian sample than in the Nigerian cohorts and the
considerable variation in the frequency among the various
samples from Nigeria could be consistent with a relatively
indistinct western border of the Bantu region in the con-
text of modern national boundaries. The observation that
the current frequency of the TTR V122I (pV142I) allele is
three times greater in coastal West Africa than in the other
parts of the continent that we were able to sample is open
to several interpretations. It is possible that the allele may
be older than the expansion, and originated in a non-
Bantu-speaking, western coastal population that was unaf-
fected by the migration, and that it has persisted in the
local populations because it is evolutionarily neutral or
under weak purifying selection. Alternatively, the allele
may have appeared after the Bantu expansion with the
lower allele frequency among the Bantu speakers represent-
ing small groups of later migrating founders.
Based on studies of over 12,000 DNA samples, the
prevalence of the allele encoding TTR pV142I allele in
African Americans is known to be 0.0173 (Jacobson et al.
2015). Furthermore, it is estimated that modern African
Americans have an average of 17% genetic admixture
with groups with non-African ancestry, although there is
substantial variation among individuals and in different
geographic regions in the United States (Kostrikis et al.
1998; Halder et al. 2009, 2012; Tishkoff et al. 2009; Bryc
et al. 2010, 2014; Murray et al. 2010; Tandon et al. 2011;
Bhatia et al. 2014; Mersha and Abebe 2015). Thus, based
on an inferred population without significant admixture
one can estimate that the average variant allele prevalence
in the African ancestors of modern African Americans
would be 0.0173/0.83 or 0.021, not significantly different
from the combined observed frequency in the high-preva-
lence area (Ghana, Sierra Leone, Guinea, Burkina Faso,
Cote d’Ivoire, and Nigeria), that is, 0.025.
Is this calculation consistent with what is known about
the Atlantic slave trade? The available historical data
indicate that 50–70% of African slaves brought to North
America came from areas corresponding to the modern
African countries included in our designation “West
Africa” plus the immediately adjacent countries of Togo
and Benin, which were not represented among our sam-
ples (whereas higher percentages of slaves from other
areas, such as modern-day Congo and Angola, for which
we do not have allele frequency data, may have been
taken, in higher numbers, to South America) (Curtin
1969). Correlating historical records of the slave trade
with modern African political boundaries is imprecise,
because of gaps in the available data and the breakdown
of Africa into geographic areas in the 16th to 19th cen-
turies (e.g., Bight of Benin [including the southern coasts
of Ghana, Togo, Benin, and the western coast of Nige-
ria], Bight of Biafra [including the presently defined
southern coast of Nigeria, Cameroon, Equatorial Guinea,
and the northern coast of Gabon], Windward Coasts,
Gold Coast [Ghana], etc.) do not precisely correspond to
modern African countries. Thus, our data and model
seem consistent with the historical record of the Atlantic
slave trade.
We conclude that the prevalence of the TTR V122I
allele in Africa ranges from 0.037 around the area pre-
sumed to include most ancestors of African Americans
to 0.010 in African countries less likely to be highly rep-
resented among the slave population brought to North
America. Haplotype data from the 1000 genomes project
are consistent with perhaps two ancient founder haplo-
types carrying the amyloidogenic rs76992529-A I allele
(Polimanti et al. 2013). Future population-based surveys
of this allele focused on smaller regions and tribal studies
within the region we have defined as “southern West
Africa” plus the adjacent areas of Togo and Benin might
reveal small areas with an even higher prevalence. Such
studies would be of interest for both genetic purposes,
and for the purposes of ultimately providing optimal
care for patients from these areas. As life expectancy in
the region increases, TTR V122I (pV142I) carriers may
represent a cohort of individuals at substantial risk of
developing clinically significant cardiac amyloidosis with
aging.
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